Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | F9 | P00740 | 2/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552074 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTHPGDNPY1RNPY2R | |
| SCHEMBL2156058 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTHPGDNPY1RNPY2R | |
| SCHEMBL2156050 | 0.70 | MAPT (0.38) | SMN1; SMN2MAPTHPGDLMNACYP1A2 | |
| SCHEMBL2156649 | 0.68 | HPGD (0.38) | SMN1; SMN2MAPTHPGDNPY1RNPY2R | |
| SCHEMBL1551484 | 0.67 | CHRM3 (0.40) | SMN1; SMN2MAPTHPGDCYP1A2CYP2C19 | |
| SCHEMBL3774175 | 0.65 | HPGD (0.37) | HPGDLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2156981 | 0.64 | MAPT (0.42) | MAPTLMNARAB9AKMT2ANPC1 | |
| SCHEMBL1551475 | 0.64 | PTGIR (0.46) | SMN1; SMN2MAPTHPGDNPY1RNPY2R | |
| SCHEMBL2155933 | 0.63 | LMNA (0.45) | SMN1; SMN2MAPTHPGDLMNACYP1A2 | |
| SCHEMBL3770444 | 0.62 | CHRM3 (0.40) | SMN1; SMN2MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891035-B1 | SUBSTITUTED BENZO-CONDENSED CYCLOHEPTANONE DERIVATIVES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2011-04-27 | — | — | EP | claimed |
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | claimed |
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | claimed |
| US-7858613-B2 | Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215858-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives And Their Use For Producing Drugs | ABCB1, DHFR, DHPS | SMN1; SMN2 3712/4885MAPT 2312/4885HPGD 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.